



Full Year 2023 Results

— March 21, 2024



Disclaimer



This presentation (“Presentation”) does not contain or constitute an offer to sell, a solicitation of an offer to buy, or a recommendation to purchase any security of Alvotech (the “Company”) to any person in the United States or in any jurisdiction to whom or in which such offer or solicitation is unlawful. Any trademarks, servicemarks, trade names and copyrights of the Company and other companies contained in this Presentation are the property of their respective owners.

Forward-Looking Statements

This Presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements generally relate to future events or future financial or operating performance of the Company and may include, for example, the Company’s expectations regarding capitalization through equity or debt financing, Alvotech’s ability to maintain listing requirements, future growth, results of operations, performance, projections of future revenue and cash runway, competitive advantages, business prospects and opportunities including pipeline product development, future plans and intentions, results, level of activities, performance, goals or achievements or other future events, the re-inspection of the Company’s manufacturing site by the FDA, the expectation that the FDA’s facility inspection in March 2023 will also serve as the pre-license inspection for AVT04, potential approval, including for AVT02 and AVT04, by the FDA and other regulatory agencies, commercial launch of the Company’s products and product candidates, including AVT02 in the U.S., the timing and progress of the announcement of clinical study results, the commencement of patient studies, regulatory approvals and market launches, the Company’s partnerships, including with Teva and information about the market opportunity of the Company’s pipeline products. In some cases, you can identify forward-looking statements by terminology such as “may”, “should”, “expect”, “intend”, “will”, “estimate”, “anticipate”, “believe”, “predict”, “potential” or “continue”, or the negatives of these terms or variations of them or similar terminology. Such forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those

expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by the Company and its management, are inherently uncertain and are inherently subject to risks, variability and contingencies, many of which are beyond the Company’s control. Factors that may cause actual results to differ materially from current expectations include, but are not limited to: (1) the outcome of any legal proceedings that may be instituted against the Company or others following the business combination between Alvotech Holdings S.A., Oaktree Acquisition Corp. II and Alvotech; (2) the ability to maintain stock exchange listing standards; (3) changes in applicable laws or regulations; (4) the possibility that the Company may be adversely affected by other economic, business, and/or competitive factors; (5) the Company’s estimates of expenses and profitability; (6) the Company’s ability to develop, manufacture and commercialize the products and product candidates in its pipeline; (7) the ability of Alvotech or its partners to respond to inspection findings and resolve deficiencies to the satisfaction of the regulators; (8) actions of regulatory authorities, which may affect the initiation, timing and progress of clinical studies or future regulatory approvals or marketing authorizations; (9) the ability of the Company or its partners to enroll and retain patients in clinical studies; (10) the ability of the Company or its partners to gain approval from regulators for planned clinical studies, study plans or sites; (11) the ability of the Company’s partners to conduct, supervise and monitor existing and potential future clinical studies, which may impact development timelines and plans; (12) the Company’s ability to obtain and maintain regulatory approval or authorizations of its products, including the timing or likelihood of expansion into additional markets or geographies; (13) the success of the Company’s current and future collaborations, joint ventures, partnerships or licensing arrangements; (14) the Company’s ability, and that of its commercial partners, to execute their commercialization strategy for approved products; (15) the Company’s ability to manufacture sufficient commercial supply of its approved products; (16) the outcome of ongoing and

future litigation regarding the Company’s products and product candidates; (17) the potential impact of the ongoing COVID-19 pandemic on the FDA’s review timelines, including its ability to complete timely inspection of manufacturing sites; and (18) the impact of worsening macroeconomic conditions, including rising inflation and interest rates and general market conditions, war in Ukraine and global geopolitical tension, and the ongoing and evolving COVID-19 pandemic on the Company’s business, financial position, strategy and anticipated milestones; and (19) other risks and uncertainties set forth in the sections entitled “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements” in documents that the Company may from time to time file or furnish with the SEC. There may be additional risks that the Company does not presently know or that the Company currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. This presentation also contains estimates and other statistical data made by independent parties and by the Company relating to market size and growth and other data about the Company’s industry. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. In addition, projections, assumptions, and estimates of the future performance of the markets in which the Company operates are necessarily subject to a high degree of uncertainty and risk. Nothing in this Presentation should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. The Company does not undertake any duty to update these forward-looking statements or to inform the recipient of any matters of which any of them becomes aware of which may affect any matter referred to in this Presentation.

Non-IFRS Financial Measures

This Presentation may include projections of certain financial measures not presented in accordance with International Financial Reporting Standards (“IFRS”) including, but not limited

to, Adjusted EBITDA and certain ratios and other metrics derived therefrom. These non-IFRS financial measures are not measures of financial performance in accordance with IFRS and may exclude items that are significant in understanding and assessing the Company’s financial results. Therefore, these measures should not be considered in isolation or as an alternative to net income, cash flows from operations or other measures of profitability, liquidity or performance under IFRS. You should be aware that the Company’s presentation of these measures may not be comparable to similarly-titled measures used by other companies. The Company believes these non-IFRS measures of financial results provide useful information to management and investors regarding certain financial and business trends relating to the Company’s financial condition and results of operations. The Company believes that the use of these non-IFRS financial measures provide an additional tool for investors to use in evaluating ongoing operating results and trends and in comparing the Company’s financial measures with other similar companies, many of which present similar non-IFRS financial measures to investors. These non-IFRS financial measures are subject to inherent limitations as they reflect the exercise of judgments by management about which expense and income are excluded or included in determining these non-IFRS financial measures. Due to the high variability and difficulty in making accurate forecasts and projections of some of the information excluded from these projected measures, together with some of the excluded information not being ascertainable or accessible, the Company is unable to quantify certain amounts that would be required to be included in the most directly comparable IFRS financial measures without unreasonable effort. Consequently, no disclosure of estimated comparable IFRS measures is included and no reconciliation of the forward-looking non-IFRS financial measures is included. For the same reasons, the Company is unable to address the probable significance of the unavailable information, which could be material to future results.

Agenda

1 Introduction

2 Commercial Update

3 Financial Update

4 Q&A

ROBERT WESSMAN

— Chairman and Chief Executive Officer

ANIL OKAY

— Chief Commercial Officer

JOEL MORALES

— Chief Financial Officer

MING LI

— Chief Strategy Officer

BENEDIKT STEFÁNSSON

— Director of IR and Global Communication



Robert Wessman

 Chairman and
Chief Executive Officer



Focused Long Term Strategy

Strategy To Address Global Healthcare Needs



Biosimilars



Infrastructure



Multi-Product Portfolio



Global Strategy

Alvotech Overview



11 disclosed molecules in the portfolio and pipeline

In-house infrastructure able to develop and manufacture complex biologics



18 World-Class commercial partners covering >90 markets globally

Dual listed (NASDAQ: ALVO) in US and Iceland



GAIN REGULATORY APPROVALS

- ✔ Simlandi® first approved high-concentration, interchangeable biosimilar to Humira® in U.S.¹
- ✔ Uzpruvo® (AVT04) first approved biosimilar to Stelara® in EU
- ✔ Jamteki™ (AVT04) first approved biosimilar to Stelara® in Canada
- ✔ AVT04 first approved biosimilar to Stelara® in Japan
- ✔ AVT04 review complete for the U.S, expect approval in April 2024



COMPLIANCE

- ✔ Established basis for successful US FDA Pre-License Inspection completed in Jan 2024
- ✔ Hosted and supported numerous regulatory and partner inspections



EXPAND COMMERCIAL NETWORK

- ✔ Expanded partnership with Teva for the U.S. market
- ✔ Expanded partnership with Fuji Pharma in Japan
- ✔ Partnership with Advanz Pharma covering 5 proposed biosimilars in Europe established



PIPELINE PROGRESSION

- ✔ AVT05, proposed biosimilar to Simponi® and Simponi Aria®, positive PK, Patient trial ongoing
- ✔ AVT06, proposed biosimilar to Eylea®, met primary endpoint from a confirmatory patient study
- ✔ AVT03, proposed biosimilar to Prolia® and Xgeva®, positive PK, Patient trial ongoing
- ✔ AVT16, proposed biosimilar to Envyio®, brought to scale-up phase
- ✔ Secured partnership with Kashiv BioSciences for AVT23 (ADL018), proposed biosimilar to Xolair® for certain

2024; A Look Ahead and Key Priorities



US LAUNCH OF SIMLANDI®

— Q2 —

First interchangeable, high concentration biosimilar to Humira



CA LAUNCH OF JAMTEKI®

— Q1 —

Aim to be the first biosimilar to Stelara, available in the Canadian Market



JP LAUNCH OF AVT04 (USTEKINUMAB)

— Q2 —

Aim to be the first biosimilar to Stelara, available in the Japanese Market



EU LAUNCH OF UZPRUVO®

— Q3 —

Aim to be the first biosimilar to Stelara, available in the European Union



AVT16 CLINICAL TRIAL INITIATION

— Q3 —

Aim to be the first company to bring a proposed biosimilar to Entyvio® into patient trials

FILINGS FOR AT LEAST 3 PROPOSED BIOSIMILARS

— Throughout '24 —

Major market filings for at least 3 additional biosimilar candidates driving additional milestone revenue

AVT04 SUPPLY INITIATION FOR U.S.

— Q4 —

Approval expected April '24 and Launch expected February '25

FURTHER PARTNERSHIP TRANSACTIONS

— TBD —

Partnering for any of the remaining unencumbered assets in the portfolio



Anil Okay

 Chief Commercial Officer



First High Concentration, Interchangeable Biosimilar to Humira



- ✔ Simlandi[®] approved by the U.S. FDA on February 23
- ✔ Inclusive of high-concentration strengths
- ✔ Interchangeable designation
- ✔ Interchangeability for the high-concentration strengths
- ✔ Exclusivity expected through April 2025 for approved presentations
- ✔ ~90% of the U.S. Humira market today comprises of high-concentration strengths

Simlandi[®] Commercial Strategy for the U.S.



PRODUCT PROFILE

- ✓ First and currently **ONLY** interchangeable, high-concentration, biosimilar to Humira[®]
- ✓ Exclusivity for interchangeable designation for high-concentration strengths for 12 months post launch
- ✓ 12 months exclusivity for IC designation



PRICING

- ✓ Two-tier pricing strategy to be employed



SUPPLY

- ✓ Alvotech facility 100% dedicated to manufacturing in-house portfolio
- ✓ Supply to partner commencing on plan
- ✓ Imminent launch



DEVICE

- ✓ Proprietary design
- ✓ In partnership with Ypsomed, a leading developer and manufacturer of injection and infusion systems
- ✓ Designed with the patient experience in mind
- ✓ Supported by 2 design focused clinical studies

AVT04; Stelara Biosimilar Update



	U.S. (AVT04)	Canada	Japan	EU
Launch	Approval expected April 16, 2024; Interchangeability License date Feb 21, 2025	Jamteki ^{TM/NC} ustekinumab injection Launched [March 10, 2024]	ウステキヌマブBS皮下注 シリンジ[FJ] Q2 '24	Uzpruvo [®] solution for injection ustekinumab Q3 '24
Partner				
Addressable Market	\$6,966M ¹	\$618M ²	\$402M ²	\$2,536M ²
Current Approved Companies	Amgen	Amgen	N/A	Samsung
Volume Trends ² CAGR% ('19-'23)	19%	21%	21%	34%

Alvotech is Pursuing a Strategically Selected Biosimilar Portfolio of Attractive Molecules



BIOSIMILAR CANDIDATE	REFERENCE BIOLOGIC	THERAPEUTIC AREA	EARLY PHASE	PRE-CLINICAL	CLINICAL TRIAL(S)		FILING	APPROVAL	LAUNCH
					PK STUDY	PATIENT TRIAL			
AVT02 High-concentration adalimumab	HUMIRA [®]	Immunology	[Progress bar]						
AVT04 Ustekinumab	STELARA [®]	Immunology	[Progress bar]						
AVT06 Aflibercept	EYLEA [®]	Ophthalmology	[Progress bar]		Positive Results ¹				
AVT03 Denosumab	PROLIA [®] / XGEVA [®]	Bone Disease	[Progress bar]		Positive Results	Ongoing			
AVT05 Golimumab	SIMPONI [®] / SIMPONI ARIA [®]	Immunology	[Progress bar]		Positive Results	Ongoing			
AVT23 Omalizumab	XOLAIR [®]	Respiratory	[Progress bar]		Positive Results	Ongoing			
AVT16 Vedolizumab	ENTYVIO [®]	Immunology	[Progress bar]						
AVT33 Pembrolizumab	KEYTRUDA [®]	Oncology	[Progress bar]						
AVT19 Undisclosed	Undisclosed	Undisclosed	[Progress bar]						
AVT28 Undisclosed	Undisclosed	Undisclosed	[Progress bar]						
AVT41 Undisclosed	Undisclosed	Undisclosed	[Progress bar]						

HUMIRA is a registered trademark of AbbVie Inc.
STELARA, *SIMPONI* and *SIMPONI ARIA* are registered trademarks of Johnson & Johnson Inc.
XOLAIR is a registered trademark of Novartis AG
PROLIA AND XGEVA are registered trademarks of Amgen, Inc.

EYLEA is a registered trademark of Regeneron Pharmaceuticals, Inc.
ENTYVIO is a registered trademark of Millennium Pharmaceuticals, Inc.
KEYTRUDA is a registered trademark of Merck Sharp & Dohme Corp.



Joel Morales

 Chief Financial Officer



FY 2023 Financial Highlights



CASH AND LIQUIDITY

- ✓ Finalized financing facilities in February 2024, providing gross proceeds of ~\$166 million.
- ✓ Giving effect to the financing, ~\$172M² of proforma cash on hand as of December 31.
- ✓ Cash on hand excludes \$25M of restricted cash.



OPERATING PERFORMANCE

- ✓ Product revenue of \$48.7m, increase of 96% versus prior year.
- ✓ Q4 2023 revenues increased 37% versus prior year
- ✓ \$42.7 million of milestone revenue, primarily due to AVT-06 development milestone (positive top line results for confirmatory clinical study).



SHARES OUTSTANDING

- ✓ 266.8 million shares outstanding as of December 31.
- ✓ Includes 39.6 million of earnout shares, of which 39.0 million not currently vested¹.
- ✓ Excludes shares to be issued for certain programs and arrangements that are not yet settled as of December 31.

¹ Includes 38.3 million Seller Earn Out Shares and 0.6 million Sponsor Earn Out Shares not yet vested, and 0.6m vested Sponsor Earn Out Shares as of December 31.

² Includes cash on hand as of December 31, and gross financing proceeds of \$166M, less financing fees of \$5M.

2024/25 Outlook

2024 Outlook

|| Revenues

\$300-400m

- ✔ Simlandi® (AVT02) launch expected in 2Q
- ✔ AVT04 launches planned in Canada, Japan and Europe. Initial pre-launch shipments to US commercial partner anticipated in Q4.
- ✔ Development and performance-based milestone revenues could comprise ~40%~50% of total revenues, driven by advancement of the pipeline and performance-based targets.

|| Cash Interest Payments

\$70-80m

|| CAPEX

\$30-35m

|| Adjusted EBITDA

\$50-150m

|| Taxes

~20%¹

2025 Outlook

|| Revenues

Up to 2x Growth



Appendix

Reported to Adjusted Reconciliation



\$ millions	12M 2023			12M 2022		
	Reported	Adjustment Entries	Adjusted	Reported	Adjustment Entries	Adjusted
Product Revenue	48,7	-	48,7	24,8	-	24,8
License and Other Revenue	42,7	1,9	44,7	58,2	2,0	60,2
Other Income	1,9	(1,9)	-	2,0	(2,0)	-
Cost of Product Revenue	(160,9)	5,2	(155,6)	(64,1)	3,1	(61,0)
R&D	(210,8)	20,3	(190,5)	(180,6)	(9,8)	(190,5)
G&A	(76,6)	14,0	(62,6)	(186,7)	127,8	(58,9)
Operating Loss	(354,9)	39,6	(315,3)	(346,4)	121,1	(225,4)
Share of Net Loss of JV	(7,2)	-	(7,2)	(2,6)	-	(2,6)
Impairment loss on inv. in JV	(21,5)	21,5	-	-	-	-
Finance Income	4,8	-	4,8	2,5	(1,6)	0,9
Finance Costs	(267,2)	132,3	(134,8)	(188,4)	108,5	(79,9)
Exchange Rate Differences	(5,2)	5,2	-	10,6	(10,6)	-
(Loss) Gain on exting. of fin. liab.	-	-	-	(27,3)	27,3	-
Loss Before Taxes	(651,0)	198,6	(452,5)	(551,6)	244,7	(307,0)
Income Tax Benefit	99,3	(8,9)	90,4	38,1	(1,7)	36,4
Loss For The Period	(551,7)	189,7	(362,1)	(513,6)	243,0	(270,5)
Loss Per Share (in \$)	(2,43)		(1,59)	(2,60)		(1,37)
EBITDA:						
Operating Loss	(354,9)	39,6	(315,3)	(346,4)	121,1	(225,4)
D&A	26,0	(2,1)	23,9	23,2	(3,1)	20,1
EBITDA	(328,9)	37,5	(291,4)	(323,3)	118,0	(205,3)

12M 2023 Adjustment Entries	
License and Other Rev./Income	<ul style="list-style-type: none"> \$1.9m of Other Income reclassified to License and Other Revenue
Cost of Product Revenue	<ul style="list-style-type: none"> \$3.3m charge related to long-term incentive plan \$1.8m impairment and \$0.3m loss on disposal of equipment (non-cash)
R&D	<ul style="list-style-type: none"> \$18.5m of one-time AR reserve pertaining to the termination of AVT23 licensing agreement with Biosana (non-cash) \$4.0m charge related to long-term incentive plan (non-cash) (\$2.3m) IP litigation costs attributable to programs - reclassified from G&A
G&A	<ul style="list-style-type: none"> \$10.8m charge related to long-term incentive plan (non-cash) \$2.3m IP litigation costs attributable to programs - reclassified to R&D \$0.9m one-time transaction costs in connection with the Iceland main board listing
Impairment loss on inv. in JV	<ul style="list-style-type: none"> \$21.5m one-time charge to reflect book value of the China JV at recoverable amount (non-cash)
Finance Costs	<ul style="list-style-type: none"> \$132.3m fair value adjustment on derivatives (non-cash)
Exchange Rate Differences	<ul style="list-style-type: none"> \$5.2m impact of exchange rate fluctuations (non-cash)
Income Tax	<ul style="list-style-type: none"> (\$7.4m) tax impact of discrete adj. in jurisdictions where tax benefits are available
12M 2022 Adjustment Entries	
License and Other Rev./Income	<ul style="list-style-type: none"> \$2.0m of Other Income reclassified to License and Other Revenue
Cost of Product Revenue	<ul style="list-style-type: none"> \$1.7m of non-cash impairment charges related to software \$1.5m of non-cash charge related to long-term incentive plan
R&D	<ul style="list-style-type: none"> (\$13.4m) IP litigation costs attributable to programs - reclassified from G&A \$3.0m of non-cash charge related to long-term incentive plan
G&A	<ul style="list-style-type: none"> \$107.1m of transaction costs incurred in connection with the merger, includes \$83.4m of non-cash listing service charge as per IFRS 2 \$13.4m IP litigation costs attributable to programs - reclassified to R&D \$6.5m of non-cash charge related to long-term incentive plan \$0.7m of non-cash impairment charges related to software
Finance Income	<ul style="list-style-type: none"> (\$1.6m) Fair value adjustment of warrants classified as derivative financial liabilities (non-cash)
Finance Cost	<ul style="list-style-type: none"> \$97.0m Fair value adjustment on derivatives \$5.0m Bond amendment (consent) fee related to the transaction close \$6.5m loss on remeasurement of bonds (non-cash)
(Loss) Gain on extinguishment	<ul style="list-style-type: none"> Loss related to the conversion of various financing arrangement (non-cash)
Exchange Rate Differences	<ul style="list-style-type: none"> Impact of exchange rate fluctuations (non-cash)
Income Tax	<ul style="list-style-type: none"> Tax impact of discrete adj. entries in jurisdictions where tax benefits are available



Thank you





Additional information

investors.alvotech.com

alvotech.com

alvotech.is

alvotech.ir@alvotech.com

